… to changing lives through the creation of transformative RNA therapies, today announced that Company management will … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNAediting technology platform, today announced that Company …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNAediting technology platform, today announced the …
First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA
… Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues across multiple … against a key Axiomer patent protecting ADAR-mediated RNAediting Well-capitalized with €139 M, in cash and cash …